leading CAR (Chimeric Antigen Receptor) T Therapy is a form of immunotherapy where doctors take your own T-cells (a type of white blood cell), genetically modify them in a lab so they can identify and kill cancer cells, and then infuse them back into your body.
Unlike chemotherapy, which affects both healthy and cancerous cells, CAR T-cells are highly targeted—reducing side effects and improving effectiveness.
| Type | Autologous CAR T | Allogeneic CAR T |
|---|---|---|
| Source | Uses the patient’s own T-cells | Uses donor T-cells (off-the-shelf) |
| Availability | Requires weeks to modify and expand cells | Readily available, faster treatment |
| Risk of Rejection | Lower risk (cells from self) | Higher risk (cells from donor) |
| Cost | Higher due to personalization | Potentially lower due to mass production |
| Suitability | Best for patients who can wait | Ideal for urgent cases or patients with weak immune systems |
| Procedure | Cells collected from the patient, modified, expanded, and reinfused | Pre-prepared donor cells infused directly into the patient |
| Process | Requires patient-specific T-cell collection, genetic modification, and expansion before infusion | Donor-derived CAR-T cells are pre-manufactured and ready for immediate infusion |
| Day | Step | Description |
|---|---|---|
| -26 | T-cell Collection (Leukapheresis) | T-cells are collected from the patient's blood. |
| -5 | Manufacturing | T-cells are genetically modified to recognize cancer antigens. |
| -3 | Patient Observation | Patient is prepared for infusion through observation and basic tests. |
| -0 | Lymphodepletion | Low-dose chemotherapy to make space for the CAR T-cells. |
| +1 | CAR T-cell Infusion | Engineered T-cells are infused into the patient |
| +15 | First Efficacy Evaluation | Doctors evaluate the early response of the therapy. |
| +30 | Discharge & Monitoring | If stable, patient is discharged and monitored remotely or via follow-ups. |
You may be eligible for CAR T Therapy if:
Note: Age isn’t a strict barrier, and SunAct has experience treating both younger and older patients.
Solid Tumors:
Blood Cancers:
Multiple Myeloma: BCMA (KaRMMa, CARTITUDE studies)
In India, cellular therapies at SunAct begin at ₹35 lakhs, a fraction of the cost in the US (₹2–3 crore).
What’s included:
Financial Support at SunAct:
Academic Excellence: MBBS; MD in Radiation Oncology and DM(Gold Medal) in Medical Oncology.
Clinical Expertise: Focus on complex solid tumors for CAR T, TCR, TIL, along with pioneering research in new drug development.
Research Innovator: Author of 700+ publications, advancing cancer treatment and understanding.
Visionary at SunAct: Promotes a multidisciplinary patient-centered approach ensuring the latest evidence-based therapies are available for optimal outcomes.
Academic Excellence: Holds MBBS, MD Medicine, DM Medical Oncology (Gold Medal), and DNB in Medical Oncology, former fellow in Clinical Hematology, emphasizing expertise in cellular therapies.
Clinical Expertise: Focus on Hematological Cancers, Stem Cell Transplants, CAR T and TCR.
Innovative Leader at SunAct: Advocates for a multidisciplinary approach, integrating the latest research into dinical practice, ensuring patients receive cutting-edge therapies and optimal care strategies.
Share your details below, and we’ll reach out to you without delay.
Disclaimer : We will be using this information for calling purposes only.
At SunAct, we don’t just follow innovation — we lead it. Here’s how we’ve changed the landscape of cancer care in India.
Yes. Centers like SunAct follow global standards with close monitoring for side effects.
You may qualify for re-infusion, TCR therapy, or clinical trials.
About 3–4 weeks, including screening, manufacturing, infusion, and monitoring.
Not anymore. SunAct performs the complete process in-house—no international travel required.
At SunAct, we believe that advanced cancer care should be within reach for everyone. That’s why we actively support patients with insurance coordination, flexible payment options, and financial assistance wherever possible.
Cellular therapies at SunAct begin at ₹35 lakhs. For Bone Marrow Transplants (BMT), we offer some of the most cost-effective options in Mumbai—without compromising on quality or safety. We also collaborate with leading GMP-compliant BMT units across India to ensure standardized, high-quality care for every patient.
Share your details below, and we’ll reach out to you without delay.
Disclaimer : We will be using this information for calling purposes only.
Share your details below, and we’ll reach out to you without delay.
Disclaimer : We will be using this information for calling purposes only.
SunAct - Advanced Cancer Therapies 4th Floor, Tieten Medicity Hospital Kasarvadavali, Ghodbunder Road Thane (West) - 400615 Maharashtra, India
SunAct - Advanced Cancer Therapies Gupte House, 3rd Floor 81, SV Road Khar West Mumbai - 400052
SunAct - Advanced Cancer Therapies 7th Floor, BMT Unit, SH8, Vengalloor Thodupuzha, Kerala – 685608
HCG Manavata Cancer Centre Manavata Health Campus, Mumbai Naka, Nashik 422002
Phone: +91 86553 13412
Toll Free: 1800 202 2232
Share your details below, and we’ll reach out to you without delay.
Disclaimer : We will be using this information for calling purposes only.
Share your details below, and we’ll reach out to you without delay.
Disclaimer : We will be using this information for calling purposes only.
